Global Biologics Contract Development and Manufacturing Organization (CDMO) Market 2024-2028

Global Biologics Contract Development And Manufacturing Organization (CDMO) Market 2024-2028

The biologics contract development and manufacturing organization (CDMO) market is forecasted to grow by USD 10.63 bn during 2023-2028, accelerating at a CAGR of 10.46% during the forecast period. The report on the biologics contract development and manufacturing organization (CDMO) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by availability of cost-efficient resources in emerging markets, strong research and development pipeline of biologics therapeutics, and growing need to focus on core competencies.

Technavio's biologics contract development and manufacturing organization (CDMO) market is segmented as below:

By Type

• Mammalian
• Microbial

By Product Type

• Biologics
• Biosimilars

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the advent of big data as one of the prime reasons driving the biologics contract development and manufacturing organization (CDMO) market growth during the next few years. Also, strategic alliances and partnerships of CDMO vendors with pharma companies and increasing approvals for new molecules and biosimilars will lead to sizable demand in the market.

The report on the biologics contract development and manufacturing organization (CDMO) market covers the following areas:

• Biologics contract development and manufacturing organization (CDMO) market sizing
• Biologics contract development and manufacturing organization (CDMO) market forecast
• Biologics contract development and manufacturing organization (CDMO) market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biologics contract development and manufacturing organization (CDMO) market vendors that include 3P BIOPHARMACEUTICALS S.L.U, AbbVie Inc., AGC Biologics, Binex Co. Ltd., Boehringer Ingelheim International GmbH, Bora Pharmaceuticals Co. Ltd, Catalent Inc., Evonik Industries AG, FUJIFILM Corp., Grifols SA, J RETTENMAIER and SOHNE GmbH and Co KG, JSR Corp., Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Novartis AG, Rentschler Biopharma SE, Samsung Electronics Co. Ltd., Shenzhen Hepalink Pharmaceutical Co. Ltd., Toyobo Co. Ltd., and WuXi Biologics Cayman Inc.. Also, the biologics contract development and manufacturing organization (CDMO) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.